Preview Mode Links will not work in preview mode


Oct 4, 2019

For those with advanced metastatic prostate cancer, treatments are limited, but a new phase 3 international trial shows that a genetically targeted therapy could offer new hope for patients with specific gene mutations in their tumors. Northwestern's Maha Hussain, MD, recently presented the results of this landmark trial and shares her insight.